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Am J Physiol Regul Integr Comp Physiol 305: R908–R916, 2013. First
published August 28, 2013; doi:10.1152/ajpregu.00102.2013.—Heart
failure (HF) is characterized by elevated sympathetic activity and
reduced parasympathetic control of the heart. Experimental evidence
suggests that the increase in parasympathetic function can be a
therapeutic alternative to slow HF evolution. The parasympathetic
neurotransmission can be improved by acetylcholinesterase inhibition.
We investigated the long-term (4 wk) effects of the acetylcholinest-
erase inhibitor pyridostigmine on sympathovagal balance, cardiac
remodeling, and cardiac function in the onset of HF following myo-
cardial infarction. Myocardial infarction was elicited in adult male
Wistar rats. After 4 wk of pyridostigmine administration, per os,
methylatropine and propranolol were used to evaluate the cardiac
sympathovagal balance. The tachycardic response caused by methyl-
atropine was considered to be the vagal tone, whereas the bradycardic
response caused by propranolol was considered to be the sympathetic
tone. In conscious HF rats, pyridostigmine reduced the basal heart
rate, increased vagal, and reduced sympathetic control of heart rate.
Pyridostigmine reduced the myocyte diameter and collagen density of
the surviving left ventricle. Pyridostigmine also increased vascular
endothelial growth factor protein in the left ventricle, suggesting
myocardial angiogenesis. Cardiac function was assessed by means of
the pressure-volume conductance catheter system. HF rats treated
with pyridostigmine exhibited a higher stroke volume, ejection frac-
tion, cardiac output, and contractility of the left ventricle. It was
demonstrated that the long-term administration of pyridostigmine
started right after coronary artery ligation augmented cardiac vagal
and reduced sympathetic tone, attenuating cardiac remodeling and left
ventricular dysfunction during the progression of HF in rats.
vagal stimulation; anticholinesterase agent; cardiac function; cardiac
remodeling; autonomic imbalance
HEART FAILURE (HF) is a frequent outcome of myocardial infarction
that is characterized by general adrenergic activation and para-
sympathetic withdrawal, which contributes to the progression of
the disease (6, 19, 49). Derangement of the vagal control of the
heart rate (HR) becomes apparent at a very early stage of left
ventricle (LV) dysfunction (7, 30) and is closely associated with
negative outcomes in patients with HF after myocardial infarction
(6). Indeed, the activation of the parasympathetic nervous system
may have beneficial implications in the development of HF (17).
Chronic vagal nerve stimulation enhanced the long-term survival
of HF rats through the prevention of contractile dysfunction and
cardiac remodeling (40). In dogs, chronic vagus nerve stimulation
attenuated the outcomes of HF and improved the cardiac auto-
nomic control reflected by increased HR variability, increased
baroreflex sensitivity, and reduced plasma norepinephrine levels
(73). In HF patients, vagus nerve stimulation performed during a
6-mo period was associated with significant improvements in
NYHA class, quality of life, a 6-min walk test, the LV ejection
fraction, and LV systolic volumes (17). Therefore, the increase in
parasympathetic function seems to be a therapeutic alternative to
improve HF outcomes by acting on the autonomic control of the
heart and improving cardiac remodeling and function.
Because efferent vagal nerve activity uses acetylcholine as the
neurotransmitter, drugs that augment acetylcholine availability at
the neuroeffector junction may be expected to have an effect
similar to electrical stimulation. Anticholinesterase agents prevent
the hydrolysis of acetylcholine by acetylcholinesterase at sites
of cholinergic transmission, which prolongs the availability of
acetylcholine in the cholinergic nerve endings and thereby
increases the efficiency of cholinergic transmission (67). Anti-
cholinesterase agents have been used in experimental designs aiming
to enhance the parasympathetic influences on the heart (19). Done-
pezil, an anticholinesterase agent that crosses the blood-brain barrier,
was administered during a 6-wk period and prevented LV dysfunc-
tion and neurohumoral activation in HF rats (48).
On the other hand, pyridostigmine (PYR) is a reversible anti-
cholinesterase agent that does not cross the blood-brain barrier
and acts specifically in the peripheral synaptic cleft (67). PYR
increased HR variability in normal rats (63), healthy humans (47),
and HF patients (5). In healthy humans, PYR given during a 1- or
2-day period produced bradycardia (20, 46) without modifying
cardiac function (18). In HF patients, PYR increased HR recovery
after exercise (2), reduced the HR and ventricular arrhythmia
density (5), and improved autonomic and hemodynamic profiles
during dynamic exercise (62). This suggests that PYR has a
modulator effect in the cardiac sympathovagal balance in normal
and HF patients. We hypothesize that the administration of PYR
right after coronary artery ligation augments cardiac vagal tone
and attenuates cardiac remodeling and LV dysfunction during the
progression of HF in rats. Hence, it is proposed in the current
study to investigate the effects of the long-term (4 wk) adminis-
tration of PYR on sympathovagal balance, cardiac remodeling,
and cardiac function in the onset of HF following myocardial
infarction in rats.
METHODS
The experimental protocols used in the current study were re-
viewed and approved by the Committee of Ethics in Animal Research
of the School of Medicine of Ribeirão Preto, University of São Paulo,
SP, Brazil (Protocol no. 1477/2007). Experiments were carried out in
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adult male Wistar rats supplied by the Animal Facility of the School
of Medicine of Ribeirão Preto, University of São Paulo, SP, Brazil.
The animals were housed individually with free access to food and
water and were maintained on a 12-h light-dark cycle.
Experimental heart failure and pyridostigmine treatment. HF was
produced by myocardial infarction according to the method described by
Pfeffer et al. (53). Briefly, rats (250–300 g, 7–8 wk old) were anesthe-
tized with ketamine (50 mg/kg ip; União Química Farmacêutica Nacional
S/A, Embu-Guaçu, SP, Brazil) and xylazine (10 mg/kg ip; Hertape Calier
Saúde animal S/A, Juatuba, MG, Brazil), endotracheally intubated, and
mechanically ventilated with room air. A left thoracotomy was performed
to expose the heart. The pericardium was opened, and the heart was
exteriorized. The left anterior descending coronary artery was ligated
between the pulmonary artery outflow tract and the left atrium with
polyester suture (4-0; Ethicon, São José dos Campos, SP, Brazil). The
heart was returned to the chest cavity, and the thorax incision was closed.
Control rats underwent similar surgical procedure without coronary
ligation (n  20). The infarct size was confirmed by postmortem
examination, and only rats with an infarct size 40% of the LV wall
were involved in the study. Overall, 103 rats were submitted to coronary
artery ligation as follows: 55 rats did not survive the surgery, 8 rats were
excluded due to infarct size 40%, and 40 rats were used in the study.
After coronary ligation, rats were randomized to groups that received
PYR administration and groups that did not. Pyridostigmine bromide
(Valeant Farmacêutica do Brasil, Campinas, SP, Brazil) was prepared
every day and was given in the drinking water (0.14 mg/ml) starting right
after the myocardium infarction. Soares et al. (63) described that this dose
of pyridostigmine bromide (0.14 mg/ml) given in drinking water during
7 days produced an average inhibition of 40% on plasma acetylcholin-
esterase activity compared with pretreatment values. Body weight and
water consumption were measured every day during the 4-wk study
protocol.
Arterial pressure and heart rate measurement. Four weeks after myo-
cardial infarction, or sham operation, the rats were anesthetized (tribro-
moethanol, 250 mg/kg ip; Sigma-Aldrich) and instrumented with poly-
ethylene catheters (Intramedic, Clay Adams, Parsippany, NJ) into the
femoral artery and vein for direct measurement of arterial pressure (AP)
and drug administration, respectively. The catheters were exteriorized on
the back of the neck, between the scapulae of the rat. After this procedure,
the animals were allowed to recover in individual cages for 48 h. On the
day of the experiment, the rats were taken to the recording room at least
30 min before the beginning of the experiment, and a quiet environment
was maintained to avoid any stress. The arterial catheter was connected
to a pressure transducer (Statham, P23 XL, Valley View, OH). Pulsatile
AP was continuously sampled (2 kHz) using an IBM/PC equipped with
an analog-to-digital interface (220, Dataq, Akron, OH). Pulsatile AP
recordings were analyzed by computer software designed to detect
inflection points of a periodic wave (Advanced CODAS, Dataq Instru-
ments). Beat-by-beat time series of systolic, diastolic, and mean arterial
pressures (MAP) were generated. HR was measured from successive
diastolic pulse intervals.
Experimental protocol. All recordings were carried out in con-
scious freely moving rats during approximately 1 h. Basal AP was
recorded during 30 min followed by measurement of the autonomic
tone (vagal and sympathetic) by means of methylatropine and pro-
pranolol (12). The HR measured when both autonomic blockers were
administered was considered the intrinsic HR (iHR). The doses of
methylatropine and propranolol were used as described previously
(16, 21). The vagal tone was measured in a group of rats after the
administration of a bolus of a solution with methylatropine (2 mg/kg
iv; Sigma-Aldrich). The difference between the HR calculated at the
end of the 15-min period after methylatropine administration and
basal HR was considered to be the vagal tone. Fifteen minutes after
the administration of methylatropine, a bolus of a solution with
propranolol (4 mg/kg iv; Sigma-Aldrich) was given to the rats, and the
AP was continuously recorded during another 15-min period for
assessment of iHR. The sympathetic tone was measured in another
group of rats after the administration of a bolus of a solution with
propranolol (4 mg/kg iv). The difference between the HR calculated
at the end of the 15-min period after propranolol administration and
the basal HR was considered to be the sympathetic tone. Fifteen
minutes after the administration of propranolol a bolus of a solution
with methylatropine (2 mg/kg iv) was given to the rats, and the AP
was continuously recorded during another 15-min period for assess-
ment of iHR. After the hemodynamic recordings, the rats were killed
by a pentobarbital sodium overdose (Rhobifarma Indústria Farmacêu-
tica, Hortolândia, SP, Brazil). The hearts and lungs were rapidly
removed, rinsed in ice-cold 0.9% NaCl solution and weighed. The
hearts were collected for morphological analysis (infarct size, myo-
cyte size, and interstitial collagen density).
Morphological analysis. The hearts were cut in the short axis, fixed
in phosphate-buffered 10% Formalin, and submitted to paraffin inclu-
sion. Each block was serially cut at 6 m from the midventricular
surface. The sections were stained with hematoxylin and eosin or
picrosirius red. For morphometric and infarct size analysis the hearts
stained with hematoxylin and eosin were used. The infarct size was
measured using the public-domain software NIH ImageJ (developed
by National Institutes of Health and available on the internet site
http://rsb.info.nih.gov/nih-image/). Infarct size was calculated by di-
viding the length of the infarcted area by the total circumference of the
LV and expressed as a percentage (55). The minor diameter of
myocytes in the surviving LV was measured using video microscopy
Leica Qwin (Leica Imaging Systems, Cambridge, UK). Approxi-
mately 30 values were obtained per rat, and the mean value was
calculated. To estimate the volume fraction (%) of collagen in picro-
sirius red-stained sections, quantitative examination of the surviving
LV was carried out on a medium-power light-microscopic field. For
each heart, 15 fields per rat were randomly selected and analyzed
using a Leica Qwin software (Leica Imaging Systems). The mean
value was subsequently calculated.
Cardiac function analysis. This protocol was performed in separate
groups of anesthetized (pentobarbital sodium) animals. Four weeks
after myocardial infarction or sham operation, rats were anesthetized
with pentobarbital sodium (40 mg/kg ip). A microtip pressure-volume
(P-V) catheter (SPR-838, Millar Instruments, Houston, TX) was
inserted into the right carotid artery and advanced into the LV as
described elsewhere (51). After stabilization, the signals were contin-
uously recorded using the P-V conductance system (MPVS, Millar
Instruments) coupled to a PowerLab/4SP (AD Instruments, Sydney,
NSW, Australia) attached to an IBM/PC. The LV end-diastolic
pressure (EDP), maximal slope of the systolic pressure increment
(dP/dt) and diastolic pressure decrement (dP/dt), relaxation time
constant (), ejection fraction (EF), stroke volume (SV), end-systolic
volume (ESV), end-diastolic volume (EDV), and cardiac output (CO)
were calculated using a cardiac P-V analysis program (PVAN Ultra
1.1, Millar Instruments) followed by corrections of cuvette and saline
calibrations as described elsewhere by Pacher et al. (51). At the end of
the experiment, the heart was collected, and the ventricles were cut
transversely into two parts. The apical portion was fixed in phosphate-
buffered 10% Formalin and stained with hematoxylin and eosin for
infarcted size analysis. The noninfarcted myocardium from the re-
maining basal part was frozen in liquid nitrogen and subjected to
Western blot analysis to determine the vascular endothelial growth
factor (VEGF) protein level.
Western blot analysis. Tissue samples were homogenized in protein
extraction buffer containing protease inhibitors (Sigma-Aldrich). Pro-
tein concentration was determined using a Bradford Assay Kit (Bio-
Rad Laboratories, Hercules, CA). Each sample of 50 g was sepa-
rated by SDS-PAGE 10%, transferred to a nitrocellulose membrane,
blocked with 5% nonfat milk in TBS-T overnight, and then incubated
with mouse anti-VEGF antibodies (1: 500, Santa Cruz Biotechnology,
Santa Cruz, CA) with 5% nonfat milk overnight. After washing was
completed, the membranes were incubated for 40 min with secondary
antibodies (anti-mouse; 1:5,000) conjugated to peroxidase. The pro-
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teins were detected by chemiluminescence using an ECL kit (Hybond-
ECL, Amersham Pharmacia Biotech, Amersham, UK). The images
were captured by a ChemiDoc XRS System (Bio-Rad Laboratories)
and analyzed by the NIH ImageJ software. GAPDH was used as a
loading control.
Acetylcholinesterase activity. A blood sample (300 l) was collected
from the rat tail before myocardial infarction and after 4 wk of PYR or
water intake. Blood samples were collected in vials containing 30 l of
EDTA (0.1 M, Sigma-Aldrich). After centrifugation (3,000 g, 4°C) for 20
min, plasma was collected and kept at 20°C until the determination of
cholinesterase activity. Enzymatic assays were performed using an ad-
aptation of the colorimetric method (24), as described by Alves-Amaral
et al. (1). Plasma samples (10 l) were incubated in 96-well microplates
with 0.01 M 5,5=-dithio-bis-(2-nitrobenzoic acid, DTNB, Sigma-Aldrich)
and the excess of the substrate (acetylthiocholine, 0.075 M, Sigma-
Aldrich) in 0.2 mM phosphate buffer, pH 8.0 at 30°C, in the presence of
the selective inhibitor of butyrylcholinesterase, tetraisopropylpyrophos-
phoramide (IsoOMPA 103 M, Sigma-Aldrich). Generation of the reac-
tion product was followed in a microplate reader (BioTek FL600, BioTek
Instruments, Winooski, VT) at 405 nm for 60 min at 3-min intervals. The
maximum velocity (Vmax) of the reaction for each sample was determined
in duplicate and expressed as arbitrary units per minute per milliliter of
plasma.
Statistical analysis. All data are presented as the means  SE.
Comparisons of the general characteristics of the animals studied,
basal AP, HR, sympathetic tone, vagal tone, iHR, VEGF, morpho-
logical, hemodynamic and cardiac function parameters, and water and
pyridostigmine intake were performed using one-way ANOVA. In
case of lack of variance homogeneity a log transformation was
employed to reach this ANOVA assumption. The Student-Newman-
Keuls test was used for post hoc comparisons. Averages of acetyl-
cholinesterase activity were compared using the one-way ANOVA for
repeated measures followed by the Student-Newman-Keuls posttest.
The level of significance was set at P  0.05.
RESULTS
General characteristics of control and HF rats with or
without pyridostigmine treatment. Representative heart sec-
tions, the general characteristics and basal hemodynamics
(MAP and HR) of control, and HF rats with or without PYR
treatment used for measuring the autonomic tone are shown in
Fig. 1. Control rats display normal LV wall thickness without
damage of the myocardium. However, an extensive scar can be
observed in the LVs of HF and HFPYR rats. Body weight
was similar in the three groups. HF rats exhibited greater heart
and lung weights than control rats. The infarct size was similar
between HF rats with PYR treatment and those without.
Control and HF rats treated with PYR showed almost the same
MAP value as those without PYR treatment. However, basal
HR was elevated in HF rats but was reduced by PYR.
Cardiac autonomic tone and intrinsic heart rate. HF rats
displayed reduced vagal tone and elevated sympathetic tone
compared with control animals (Fig. 2). The greater tachy-
cardic response caused by methylatropine in HFPYR rats
indicates an augmented vagal tone compared with HF rats (Fig.
2). On the other hand, the smaller bradycardic response caused
by propranolol in HFPYR rats indicates a less sympathetic
tone compared with HF rats (Fig. 2). Moreover, the combined
administration of methylatropine and propranolol shows that
PYR did not affect the iHR of HF rats (control: 377  5; HF:
392 6; HFPYR: 394 8 beats/min). The administration of
methylatropine and/or propranolol did not affect the AP.
Myocyte size, interstitial fibrosis, and VEGF protein. The minor
diameter of the myocytes (Fig. 3), collagen density (Fig. 4),
and VEGF protein level (Fig. 5) from the surviving LV of HF
rats was significantly greater compared with control rats. In HF
rats, both minor diameter of the myocytes (Fig. 3) and collagen
density (Fig. 4) were reduced by PYR. However, PYR in-
creased the VEGF protein expression in the surviving LVs of
HF rats (Fig. 5).
Hemodynamic and cardiac function. The infarct size of HF
rats treated with PYR (56  2%) was almost the same as those
from HF rats without PYR treatment (59  2%) when used in
the hemodynamic and cardiac function studies. Table 1 shows
the weight, hemodynamic parameters, and the indices of sys-
Control 
(n=13) 
HF 
(n=12) 
HF+PYR 
(n=14) 
BW (g) 474 ± 12 447 ± 14 435 ± 11 
HW (mg) 1355 ± 31 1536 ± 33* 1589 ± 51* 
LW (mg)  1299 ± 60 1804 ± 90* 1617 ± 80* 
Infarct Size (%LV)                 -                    57 ± 1                    53± 2 
MAP (mmHg) 103 ± 2 103 ± 3 94± 4 
HR (bpm) 335 ± 5  388 ± 11*  347 ± 4† 
HW/BW ratio (mg/g) 2.9 ± 0.1 3.5 ± 0.01* 3.6 ± 0.1* 
LW/BW ratio (mg/g) 2.5 ± 0.1 3.9 ± 0.2* 3.5 ± 0.2* 
Fig. 1. Heart sections (Masson’s trichrome stained), the general
characteristics and basal hemodynamics of control, and heart
failure (HF) rats with or without pyridostigmine (PYR) treat-
ment. Values are presented as the means  SE; BW, body
weight; HW, heart weight; LW, lung weight; MAP, mean
arterial pressure; HR, heart rate. Bar  2 mm. *P  0.05
compared with the control group, †P 0.05 compared with the
HF group.
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tolic and diastolic function from P-V relations in anesthetized
rats. The parameters obtained from P-V analysis confirmed
that rats submitted to myocardial infarction developed HF.
These rats exhibited remarkable increases in EDP, ESV, and .
In addition, they also showed conspicuous reduction in SV, EF,
CO, dP/dt, and dP/dt compared with control rats (Table 1).
PYR increased the SV, EF, CO, and dP/dt in HFPYR
rats.
*
*
†
†
B
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SYMPATHETIC TONE
Propranolol + Atropine
2 min
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)
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H
)
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R
H
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A
Fig. 2. A: representative heart rate (HR) series from a control (light gray lines) and HF rats with (solid lines) or without PYR treatment (dark gray lines) that
received methylatropine (top) and propranolol (bottom). B: tachycardic response caused by methylatropine (top) and bradycardic response caused by propranolol
(bottom) in control and HF rats with or without PYR treatment. Values are presented as the means  SE; HR, heart rate; the number inside the bar represents
the number of animals of the respective group. *P  0.05 compared with the control group; †P  0.05 compared with the HF group.
Fig. 3. Photomicrographs and bar graphs of
the minor diameter of myocytes from the left
ventricle of control and HF rats with or
without PYR treatment. Values are pre-
sented as the means SE; the number inside
the bar represents the number of animals of
the respective group. Bar  50 m. *P 
0.05 compared with the control group; †P 
0.05 compared with the HF group.
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Pyridostigmine intake and acetylcholinesterase activity.
Water consumption was similar among the three groups stud-
ied (control: 55  2; HF: 51  1; HFPYR: 54  1 ml/day).
PYR intake was	21 mg·kg1·day1 for HF rats. The effect of
PYR on plasma acetylcholinesterase activity is shown in Fig. 6.
Plasma acetylcholinesterase activity decreased 42% in HF rats
treated with PYR compared with pretreatment values.
DISCUSSION
This study shows that chronic administration (per os) of the
acetylcholinesterase inhibitor PYR reduced HR, increased car-
diac vagal tone, and reduced sympathetic tone. Likewise, PYR
attenuated the cardiomyocyte hypertrophy, the collagen ex-
pression in the noninfarcted myocardium, and the decline of
the systolic LV function during the progression of HF follow-
ing myocardial infarction.
The current study is in line with previous observations (6,
22, 34, 54, 75) and demonstrates elevated cardiac sympathetic
tone and attenuated parasympathetic tone in conscious HF rats,
Fig. 4. Photomicrographs and bar graphs of
the collagen density from the left ventricle of
control and HF rats with or without PYR treat-
ment. Values are presented as the means  SE;
the number inside the bar represents the num-
ber of animals of the respective group. Bar 
50 m. *P  0.05 compared with the control
group; †P  0.05 compared with the HF
group.
VEGF 15 kDa
GAPDH 37 kDa
Control HF HF+PYR 
*
*
Fig. 5. Vascular endothelial growth factor (VEGF) protein expression (West-
ern blot analysis) in control and HF rats with or without PYR treatment. The
number inside the bar represents the number of animals of the respective
group. *P  0.05 compared with the control group; †P  0.05 compared with
the HF group.
Table 1. Hemodynamic parameters and indices of left
ventricle systolic and diastolic function derived from
pressure-volume relations in anesthetized control and HF
rats with or without PYR treatment
Control HF HFPYR
Weight, g 526  40 448  20 453  20
EDP, mmHg 7  0.5 16  3* 13  1*
ESV, l 155  20 240  20* 199  16
EDV, l 253  22 280  21 256  20
SV, l 98  2 41  6* 62  4*†
EF, % 40  4 15  2* 28  4*†
CO, ml/mi) 36  4 13  2* 20  2*†
dP/dt, mmHg/s 10,111  523 5,114 355* 6,437 249*†
dP/dt, mmHg/s 11,370  810 3,941  255* 4,598  244*
, ms 12  1 22  3* 25  2*
Values are means  SE; n  7. EDP, end-diastolic pressure; ESV,
end-systolic volume; EDV, end-diastolic volume; SV, stroke volume; EF,
ejection fraction; CO, cardiac output; dP/dt and dP/dt, maximal slope of
the systolic increment and diastolic decrement of ventricular pressure, respec-
tively; , relaxation time constant; HF, heart failure; PYR, pyridostigmine.
*P  0.05 compared with the control group; †P  0.05 compared with the HF
group.
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without change in the iHR, which might explain the tachycar-
dia exhibited by this group of animals. A lower iHR in patients
with HF may indicate impaired sinus node function (50).
However, HF rats treated with PYR did not show any cardiac
autonomic abnormality. HF rats treated with PYR showed HR,
vagal tone, and sympathetic tone quite similar to those ob-
served in control rats, indicating that PYR prevented the
sympathovagal imbalance, the usual outcome observed during
the development of HF. The increase in cardiac parasympa-
thetic tone in HF rats produced by PYR may be due to the
improvement of cholinergic neurotransmission in the sinus
node. The pharmacological effect of PYR might be attributed
to the inhibition of acetylcholinesterase, which was 42% less
than control values, with consequent accumulation of endoge-
nous acetylcholine in the vicinity of the nerve endings in the
heart, producing effects similar to vagal nerve stimulation (19,
67), for instance, bradycardia.
The increase in parasympathetic tone in HF rats treated with
PYR was accompanied by a significant decrease in the cardiac
sympathetic tone. The neural control of the heart is exerted by
the tonic interaction between the sympathetic and parasympa-
thetic arms of the autonomic nervous system (60). It has
previously been proposed that parasympathetic stimulation is
able to inhibit the sympathetic drive (38). Acetylcholine can
act on muscarinic receptors situated in sympathetic presynaptic
nerve endings inhibiting the release of norepinephrine (4, 41,
45). The interaction between the sympathetic and parasympa-
thetic nervous system may also be partially modulated by
second messengers in cardiac cells (49), where cholinergic
stimulation may inhibit the increase of intracellular cAMP
(72), inhibiting the adrenergic signaling cascade (38).
It has been documented that on the sinoatrial node the
parasympathetic modulation predominates over the sympa-
thetic activity (28, 58, 71). This response is known as “accen-
tuated antagonism” (38). When a vagal electrical stimulation is
applied simultaneously to a sympathetic electrical stimulus,
there is a reduction in HR similar to that observed in the
presence of vagal stimulation alone (37). Moreover, in deter-
mining the amount of circulating norepinephrine in a dog’s
coronary sinus, there was a reduction of this neuromediator
when the vagus nerve was activated simultaneously with the
sympathetic nerve (36). The results from the current study
suggest that the parasympathetic improvement produced by
PYR in HF rats was able to suppress the augmented sympa-
thetic drive to the heart. The level of sympathetic activity is
closely related to the severity of symptoms seen in HF (13),
and the reduction of cardiac sympathetic tone can provide
beneficial influences in the prognosis of this disease.
One of the consequences of myocardial infarction is the
remodeling of the surviving myocardium, which is character-
ized by both interstitial fibrosis (70) and hypertrophic growth
of cardiac myocytes and capillary rarefaction (3). This remod-
eling may affect the LV function and consequently HF devel-
opment and the prognosis for survival (52, 70). In the present
study, PYR attenuated the collagen accumulation and the
myocyte hypertrophy in the surviving LV in HF rats. Sympa-
thetic hyperactivity can contribute to morphological changes
and functional deterioration of the myocardium. Adrenergic
activation increases the heart wall stress, which accelerates the
tissue injury process (42), and directly affects the myocardium
through the catecholamine cardiotoxic effects, inducing myo-
cardial necrosis and capillarization disturbance (11, 57, 69).
Recent study showed that PYR was effective in preventing the
hypertrophic effect of isoproterenol in neonatal cardiomyo-
cytes maintained in culture (56). HF rats that received PYR
showed reduced sympathetic cardiac tone, which may have
helped to attenuate the cardiac remodeling.
Moreover, the cardiac morphological alterations produced
by PYR can also be associated with the reduction of the HR. It
is well known that tachycardia increases the myocardial oxy-
gen consumption and reduces the coronary perfusion time,
decreasing the myocardial oxygen supply, contributing to tis-
sue injury and the subsequent HF (75). The reduction of the
HR leads to decreased myocardial oxygen consumption and
increased diastolic period of the cardiac cycle, which enhances
the coronary perfusion time, increasing both myocardial per-
fusion and oxygen supply (8, 65). These effects could have an
antiremodeling action following the improvement of the sur-
viving myocardial energetic balance (44).
HR reduction in HF rats is associated with angiogenesis in
postinfarcted hearts (10, 35). Previous studies have shown that
drug-induced bradycardia enhances vascularity and coronary
reserve, preserving the function of the surviving myocardium
(10, 35). This angiogenic response is dependent on VEGF (35,
74). It has been documented that after myocardial infarction
the VEGF is increased in the surviving myocardium (29, 39,
64, 66) as observed in the current study. Despite the increase of
VEGF in HF rats, previous studies have shown that neovascu-
larization in the surviving myocardium is not able to maintain
the adequate tissue perfusion (32, 33). In the present study,
PYR augmented the VEGF protein level, suggesting increased
angiogenesis in the surviving myocardium. The expansion of
the capillary bed in the affected vasculature of the heart can
prevent cardiac remodeling and support better pumping capac-
ity (10, 35).
The current results indicate that the increase in the cardiac
vagal tone produced by PYR attenuated the LV dysfunction in
HF rats. Studies have shown that chronic electric vagal stim-
ulation improves the cardiac function in HF rats (40) and dogs
(73). Okazaki et al. (48) also observed an increase in the LV
contractility after the chronic administration of the anticholin-
esterase agent donepezil in HF rats. The beneficial effects of
PYR in cardiac function in HF rats could be related to the
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Fig. 6. Plasma acetylcholinesterase (AChe) activity in control and HF rats with
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prevention of modifications in the LV structure, i.e., a reduc-
tion of both collagen accumulation and myocyte hypertrophy
in the surviving LV and a likely angiogenesis improvement.
Furthermore, there is in vitro evidence that sympathetic stim-
ulation induces apoptosis in cardiac myocytes, contributing to
myocardial dysfunction (14). Muscarinic receptor stimulation
produced by carbachol can prevent the apoptosis induced by
norepinephrine (15), suggesting that muscarinic activation can
improve myocardial function by this mechanism (49). Reduc-
tion in the diameter of cardiomyocytes from HF rats that
received PYR was not accompanied by heart weight reduction.
The presence of greater number of surviving myocytes in the
viable myocardium from HF rats treated with PYR indicates
that more myocytes have been spared. Thus the higher number
of cells in the viable LV may be due to the reduction of
apoptosis. Nevertheless, further studies are required to confirm
this notion.
The EF values measured in control rats using the P-V
catheter were lower (40%) compared with values obtained by
echocardiography, i.e., around 80% for a normal rat and less
than 40% for the HF rat. It has been shown in the literature that
both methods, echocardiography and pressure-volume conduc-
tance, provide highly correlated (r  0.95) different values for
EF (25, 31). However, the EF observed in the current study,
40% for control rats and 15% for HF rats, are lower when
compared with other studies that used the P-V conductance
method, and observed values between 52 and 59% in control
rats and between 27 and 36% in HF rats (26, 31, 51, 61).
In our laboratory Sabino et al. (59) showed that PYR was
able to prevent the reduced baroreflex sensitivity, cardiac
parasympathetic tone, and iHR in HF rats, 6–7 wk after
coronary artery ligation. However, PYR did not prevent the
decrease of basal AP and cardiac performance (59). In the
current study the effects of the acetylcholinesterase inhibitor
PYR on sympathovagal balance, cardiac remodeling, and car-
diac function were investigated in the onset of HF, i.e., 4 wk
following myocardial infarction. These data are in line with
those from Sabino et al. (59) concerning an increase in the
cardiac parasympathetic tone. However, in contrast to Sabino
et al. (59) observations, the current study demonstrated de-
creased cardiac sympathetic tone and improvement of the LV
dysfunction combined with attenuation of the cardiac remod-
eling in HF rats treated with PYR. Therefore, the difference
between the current study and the previous from Sabino et al.
(59) could be attributed to the difference in time course, i.e., 4
versus 6–7 wk postmyocardial infarction.
Nevertheless, the current study was the first to show that
PYR was able to reduce the cardiac sympathetic activation and
attenuate the decline in systolic LV function and the cardiac
remodeling in HF rats. Previous studies showed that physical
and pharmacological enhancement of parasympathetic func-
tion decreased sympathetic activation and improved the cardiac
function in HF animals (40, 48, 73). However, these studies did
not describe alterations in cardiac remodeling, attenuation of
cardiomyocyte hypertrophy, and collagen expression in the
noninfarcted myocardium, as described in the present study.
In conclusion, long-term (4 wk) administration of PYR
started right after coronary artery ligation augmented cardiac
vagal and reduced sympathetic tone. Likewise, PYR attenuated
the increase in cardiomyocyte hypertrophy, the collagen ex-
pression in the noninfarcted myocardium, and the decline in
systolic LV function during the progression of HF.
Perspectives and Significance
HF is characterized by a chronic sympathovagal imbalance
that contributes to the pathophysiology and progression of the
disease. It has been demonstrated that a high level of parasym-
pathetic activation provides cardioprotection by means of sev-
eral potential mechanisms. Even though vagus nerve stimula-
tion appears to be safe and well tolerated by patients (17), the
pharmacological approach of parasympathetic activation for
treatment of HF has the advantage of being noninvasive and
appeared to be quite efficient.
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